Table 2.
Baseline cGVHD Characteristics
| Pt # | Age | Sex | Average NIH cGVHD Score at baseline | cGVHD affected organs at baseline | Evaluable joints at baseline | Concomitant ISM | % BSA moveable sclerosis (baseline) | % BSA nonmoveable sclerosis (baseline) | Baseline ROM % (of predicted) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 56 | M | 1.28 | 5 | 3 | Pred/tacro | 57.15 | 7.56 | 37% |
| 2 | 60 | M | 1.14 | 4 | 3 | Pred | 2.7 | 56.7 | 56% |
| 3 | 10 | F | 0.75 | 3 | 2 | MPred/MTX | 6.3 | 36.9 | 73% |
| 4 | 52 | F | 1.0 | 4 | 3 | Pred/siro | 0.18 | 19.98 | 7% |
| 5 | 30 | M | 1.48 | 6 | 3 | Pred/siro/tacro | 8.1 | 77.94 | 34% |
| 6 | 51 | M | 1.86 | 7 | 3 | MPred/tacro/siro/MMF | 59.4 | 0 | 47% |
| 7 | 55 | F | 1.90 | 7 | 3 | Pred/siro/MMF | 29.7 | 32.4 | 61% |
| 8 | 58 | M | 1.57 | 6 | 3 | Tacro | 15.3 | 36.9 | 35% |
| 9 | 60 | M | 1.71 | 7 | 3 | Pred/tacro/siro | 3.33 | 9 | 42% |
| 10 | 53 | M | 1.43 | 5 | 3 | Tacro/MMF | 0 | 8.28 | −7% |
| 11 | 28 | F | 1.75 | 7 | 3 | Pred/siro/MMF | 82.08 | 0 | 56% |
| 12 | 56 | M | 1.43 | 6 | 3 | Tacro/MMF | 12.6 | 8.64 | 37% |
| 13 | 34 | F | 1.38 | 6 | 3* | Pred/tacro | 1.8 | 71.1 | 27% |
| 14 | 46 | M | 1.29 | 5 | 3 | Pred/MMF | 5.4 | 31.5 | 32% |
| 15 | 55 | M | 1.43 | 6 | 3 | Pred/siro | 49.77 | 10.8 | 22% |
| 16 | 55 | M | 0.86 | 2 | 1 | Siro/MMF | 0 | 9.54 | 71% |
| 17 | 7 | F | 1.13 | 4 | 3 | MPred/tacro/MMF | 84.24 | 0 | 64% |
| 18 | 21 | M | 1.57 | 4 | 3 | Siro | 15.84 | 4.5 | 54% |
| 19 | 48 | M | 1.14 | 4 | 3 | Tacro/MMF | 9.45 | 11.7 | 33% |
| 20 | 18 | M | 2.00 | 7 | 3 | None | 0 | 23.4 | −5% |
ISM = immunosuppressive medication, Pred = prednisone, MPred = methylprednisolone, MTX = methotrexate, siro = sirolimus, tacro = tacrolimus, MMF = mycophenolate mofetil.
*
Note: Pt #13 started with 3 measureable joints at enrollment on study. She experienced an episode of acute shoulder pain while on study and evaluation revealed avascular necrosis of that shoulder. Therefore, only 2 joints were used in the final analysis.